Clinical Trials
8 trialsNCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03656718 2025-11-12
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04572451 2025-08-01
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Phase 1 Recruiting
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01629758 2015-03-06
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed